Item 8.01. Other Events
On October 26, 2022, Statera Biopharma, Inc. (the "Company") received a
determination from a Nasdaq Hearings Panel (the "Panel") granting the Company's
request for the continued listing of its common stock on The Nasdaq Capital
Market ("Nasdaq"), subject to the Company's satisfaction of certain interim
milestones and, ultimately, the Company's compliance with all applicable
criteria for continued listing on Nasdaq, including the $1.00 bid price and $2.5
million stockholders' equity requirements as set forth in Nasdaq Listing Rules
5550(a)(1) and 5550(b)(2), respectively, by no later than January 31, 2023. The
Company is taking definitive steps to timely evidence compliance with the terms
of the Panel's decision; however, there can be no assurance that it will be able
to do so.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that are
based on management's beliefs and assumptions and on information currently
available to the Company's management. Forward-looking statements include
statements regarding the Company's expectations regarding the submission of a
compliance plan to Nasdaq. Forward-looking statements include statements that
are not historical facts and can be identified by terms such as "anticipate,"
"believe," "could," "estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "seek," "should," "will," "would" or similar expressions
and the negatives of those terms. The Company's actual results and the timing of
events could materially differ from those anticipated in such forward-looking
statements as a result of certain risks and uncertainties including those
described in more detail in the Company's most recent Annual Report on Form 10-K
and other documents on file with the SEC, each of which can be found on the
SEC's website, www.sec.gov, or the investor relations portion of the Company's
website, https://ir.staterabiopharma.com/financial-information/sec-filings.
Except as required by law, the Company assumes no obligation to update these
forward-looking statements, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking statements, even if
new information becomes available in the future.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses